What TROA is
The Treat and Reduce Obesity Act (TROA) — currently introduced as H.R. 4231 in the House and S. 1973 in the Senate — is federal legislation aimed at expanding Medicare coverage for obesity treatment. It's the piece of federal legislation most directly connected to the gap covered in our guide on the push to get Medicare to cover GLP-1 medications: the 2003 statutory exclusion of "agents used for weight loss" from Medicare Part D.
What it would actually change
According to the Obesity Action Coalition, TROA proposes two specific changes to Medicare:
- Medications: It would allow Medicare Part D to cover FDA-approved prescription drugs for obesity treatment — drugs that are currently excluded outright under the existing federal statute, regardless of clinical appropriateness for a given beneficiary.
- Behavioral therapy access: It would broaden Medicare's current, narrowly restrictive National Coverage Determination for intensive behavioral therapy for obesity, allowing more types of healthcare professionals and care settings to deliver these services — not just the limited settings currently permitted.
Its legislative history
TROA has been reintroduced repeatedly across more than a decade of congressional sessions, consistently with bipartisan support, but has not yet passed into law. Separately, the Centers for Medicare & Medicaid Services (CMS) recently launched the BALANCE Model, an administrative program aimed at expanding obesity medication access through a different mechanism than legislation. According to the Obesity Action Coalition, despite that administrative effort, TROA "remains the primary way for members of Congress to demonstrate support for lasting improvements in obesity care" — meaning it continues to serve as the clearest legislative vehicle for this specific policy change, separate from whatever administrative programs exist at a given time.
Who's behind it
The Obesity Action Coalition (OAC) is a leading advocate for TROA, and maintains a dedicated resource page tracking the bill: obesityaction.org/troa (external link). This is a useful primary source to check for the bill's current status, since legislative tracking changes session to session.
How to get involved
TROA is a clear example of the kind of sustained, multi-year advocacy effort described in our guide on the role of patient advocacy organizations in obesity treatment policy. Because it's been reintroduced repeatedly without yet passing, continued visible constituent support — contacting your representatives, supporting organizations actively lobbying for it, and staying current on its status each session — is part of what keeps it moving rather than stalling out entirely.
The bottom line
TROA is the standing legislative answer to Medicare's outdated exclusion of obesity medications — narrowly scoped, repeatedly reintroduced, and not yet law. Anyone interested in Medicare coverage for GLP-1 medications should treat it as the primary bill to track and support at the federal level.